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ABSTRACT
Oropharyngeal cancers caused by human
papillomaviruses (HPV) have a different
epidemiology, prognosis, genetic mutational
landscape, response to treatment, and
outcome when compared to HPV-negative
cancers. In this review, a summary of our
current understanding of HPV in head and
neck cancer and the important advances that
have shown HPV to be an etiological agent are
discussed. HPV-positive and HPV-negative
tumors are compared discussing
clinicopathological factors, prognosis, outcome
following treatment, and the molecular and
genetic differences. Currently, the standard of
care for oropharyngeal cancer is both surgery
and post-operative radiotherapy with or
without cisplatin or concurrent
chemo-radiotherapy. The latter is used more
often, especially in cancers of tonsil and base of
tongue. However, there is increased interest in
trying to de-intensify treatment and in the
development of new treatments to target the
underlying different molecular pathways of
HPV-positive cancers. The current clinical
trials involving surgery, chemotherapy, and
radiation therapy are discussed. The new
targeted treatments are also summarized.
Although there is currently is no evidence
from prospective studies to support a change
in the treatment algorithm, the treatment
options for patients with HPV-positive disease
are likely to change in the future.
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BACKGROUND
Squamous cell carcinoma (SCC) is the most
common histological cancer type to affect the
mucosal surfaces of the upper aero-digestive
tract, accounting for 89% of cancer types [1].
Whilst the incidence of SCC in most of the
major sites in the head and neck have reduced
or remained static, the incidence of
oropharyngeal SCC has increased [2]. In a
United States (US) study examining data from
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the Surveillance, Epidemiology, and End Results
(SEER) programme, the incidence of
oropharyngeal cancers increased by 1.3% for
tongue base cancers and by 0.6% for cancers of
the tonsil for each year between 1973 and 2004
[3]. In contrast, the incidence of oral cavity
cancers has declined by 1.9% every year during
this period [3]. This has been seen worldwide,
particularly in the developed world [4]. This is
demonstrated in Fig. 1, adapted from the data
supplement from Chaturvedi et al. [4].
Head and neck SCC has been associated
with tobacco smoking, and the cancer
incidence in these anatomical sites has
mirrored smoking rates [5]. There has been a
decreasing trend in tobacco usage in the
developed world and decreasing rates of head
and neck cancer in all mucosal sites, except for
the oropharynx [6].
Human papillomavirus (HPV) was first
identified as a possible etiological agent in oral
SCC in 1983 [7]. The oncogenic potential of
HPVs in squamous epithelium has been
understood for many years following work in
uterine cervix and ano-genital squamous cell
cancers [8]. A causal link between HPV and
oropharyngeal cancer was shown in a study by
Gillison et al. [9], which added further support
to the epidemiological and molecular evidence
for HPV as the etiological factor in the
increasing incidence of oropharyngeal SCC
[10]. The International Agency for Research on
Cancer in 2007 added HPV type 16 as a cause of
oropharyngeal carcinoma [11].
Importantly, oropharyngeal cancers due to
HPV have a different epidemiology, prognosis,
response to treatment, and outcome. The
implications of this for therapy are under
investigation, and this subset of patients may
be able to undergo treatments with less toxicity.
It may also allow for targeted therapies related
to the different underlying molecular genotype.
This review presents a summary of HPV related
oropharyngeal carcinoma and highlights
potential therapeutic options that may
become available for these patients. This
article is based on previously conducted
studies and does not involve any new studies
Fig. 1 The net drift percentage (net drift represents the net
sum of the linear trend in period and cohort effects from
age-cohort-period models) in oropharyngeal and oral cavity
cancers among men stratiﬁed by age (1983–2002) for
selected countries [4]. Black square oropharynx, white
square oral cavity. Adapted with permission from
Chaturvedi et al. [4]
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of human or animal subjects performed by any
of the authors.
HPV AND OROPHARYNGEAL SCC
HPVs comprise 150 small non-enveloped DNA
viruses that have double-stranded and circular
genomes [12]. They share a similar segment in
their genome called the L1 gene that encodes
for the major capsid protein. They can be
divided into mucosal and cutaneous types.
They are further classified into high-risk and
low-risk viruses depending on their ability to
induce cancer. HPV 16 is a high-risk virus that
has been associated with up to 90% of
HPV-related head and neck cancer in mucosal
surfaces. The other HPV genotypes have a
prevalence of less than 5% in oropharyngeal
tumors [13, 14].
The life cycle of HPV viruses is closely related
to the differentiation of the squamous cell it
infects [12]. Initially the virus targets and infects
the basal squamous cells at the deep aspect of
the skin or mucosa. It will gain access after
trauma or erosion of the superficial layers. A low
virus genome copy count of approximately ten
is maintained in these cells. The virus is able to
take over the cell’s replication machinery [15]
and maintain the cell’s ability to synthesize
DNA, which is usually lost as the cell
differentiates. As the cell starts differentiation,
the productive phase of virus replication is
started, where up to 1000 viral genome copies
are produced along with expression of the viral
L proteins [12]. Mature virus progeny particles
are then released into the uppermost layers of
the epithelium.
The tonsil epithelium has a specialized
morphology. The tonsil has multiple crypts,
and these have specialized stratified squamous
non-keratinizing epithelium and patches of
reticulated sponge-like epithelium [16]. These
perform a function in antigen recognition as
part of the immune system [16]. HPV is thought
to access the oropharyngeal mucosa via the
tonsillar crypts [17], through the specialized
porous membrane. The mechanism of viral
entry into the cell is not fully understood, but
is thought to involve a6b4 integrins [18] and
cell surface heparin sulfate proteoglycans
(HSPGs) [19]. Once a cell is infected, the
natural history of infection is not well
understood in the oropharynx. The proportion
of infections that enter an acute, chronic, or
latent phase or are cleared by the host’s
immune system is not clear [12]. However, it
is thought that most oral HPV infections are
cleared within a year [20].
A prevalence study in the US as part of the
National Health and Nutrition Examination
Survey (NHANES) in 2009–2010 [21] showed
the prevalence of oral HPV infection among
men and women aged 14–69 years was 6.9%
and of HPV type 16 was 1.0%. A more recent
systematic review showed a prevalence of 4.5%
in 4070 subjects for any HPV type [22] and
prevalence of 1.3% for HPV 16. The implication
of HPV 16 infection was shown in a case control
study in which an odds ratio of 14.6 [95%
confidence interval (CI), 6.3–36.6] was seen in
patients with newly diagnosed oropharyngeal
cancer compared to cancer-free controls [23].
Following infection with HPV there is a
latency period and a stepwise progression
towards genomic instability [12] before cancer
can develop. The viral genes and proteins E6,
E7, and also E5 are involved in carcinogenesis.
The key step is the integration of the viral genes
into the host genome usually as an epitome
[24].
There are two common molecular
mechanisms by which the virus causes
genomic instability. Firstly, the E6 protein
binds to host cells’ p53 and with the cellular
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ubiquitin ligase E6-associated protein (E6AP)
causes degradation of the cellular p53 protein
[25]. This impairs cellular apoptosis providing a
step towards allowing cells to become
immortalized.
Secondly, the E7 protein binds and
inactivates the retinoblastoma (Rb) protein. Rb
regulates the activity of E2F (a transcription
factor that regulates cell cycle progression) [24].
By inactivating Rb, levels of E2F are increased
which promotes cell cycle progression. This
occurs by allowing increased expression of
p16, a cyclin-dependent kinase inhibitor that
functions as a checkpoint inhibitor [26]. Further
investigation has shown both of these proteins
to be multifunctional [27]. The E6 protein has
a-helix-binding partners and PDZ-binding
partners, which have been shown to
contribute to tumorigenesis in other tissues
and are likely to be implicated in head and
neck cancer carcinogenesis [27]. These protein
interactions have been reported to involve at
least 30 different cellular substrates [28], with
effects on polarity/tumor suppression, signal
complex scaffolds, TGF-b signaling, PI3K/AKT
signaling, tight junction assembly, and a
number of other cellular functions.
Both the detection of HPV DNA and the
identification of p16 as a surrogate for infection
have been correlated with outcome in these
patients [29]. The E5 protein is thought to
increase epidermal growth factor receptor
(EGFR) recycling to the cell surface, and this
has been seen in cervical cancers [30], but its
role in head and neck cancer is yet to be
defined.
There are a number of different ways to
detect HPV infection, but there is no worldwide
consensus on which is best. Each detection
method has its own associated strengths and
weaknesses, and methods vary throughout the
world [31]. The main aim is to identify
transcriptionally active high-risk HPV.
Methods vary from routine histology,
polymerase chain reaction (PCR) for viral DNA
or RNA, in situ hybridization to
immunohistochemistry. The identification of
high-risk HPV DNA and the over-expression of
p16 (a surrogate marker for infection) are






Following the application of highly sensitive
HPV detection methods and a rigorous
definition of active HPV transcription, the vast
majority of HPV-positive tumors have been
shown to be located in the oropharynx,
mostly in the tongue base and tonsil [31], and
rarely in other head and neck sites. The
correlation of HPV-related tumors and
high-risk sub-sites in Waldeyer’s ring is an
important and significant difference between
HPV-positive and HPV-negative tumors. Two
large meta-analyses have shown HPV infection
is strongly associated with tonsillar and base of
tongue sites [33, 34]. However, it is important to
understand that the testing method can be a
source of heterogeneity when comparing
studies [33]. In contrast, HPV-negative tumors
do not have a predilection to a particular
sub-site in the head and neck [35] and field
cancerization is more common.
In modern series, approximately 50% of
oropharyngeal cancers have detectable HPV
DNA on testing [36], with some reporting
higher rates, depending on the studied
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population. In a United Kingdom (UK) series,
HPV-related cancers were identified in 70% of
the oropharyngeal tumors [37]. The high-risk
HPV 16 subtype is found in 90% of these
cancers with other high-risk subtypes 31, 33,
and 18 identified in the other cases [36]. In
comparison, transcriptionally active high-risk
HPV DNA is rarely seen in other sites in the
head and neck and in oropharyngeal sub-sites
such as the soft palate and posterior pharynx
[37].
The investigation of population-level data
has been possible due to the difference in tumor
sub-sites between HPV-positive and
HPV-negative cancers [3]. In a 2008 analysis of
SEER data from 1973 to 2004, patients with
tumors that were likely to be HPV-positive by
sub-site were significantly younger, 61.0 versus
63.8 years, P\0.001 [3]. This was also seen in a
series of 193 patients, in which patients with
HPV-positive cancers on DNA PCR were
significantly more likely to be less than
55 years old [38]. Age was also identified as an
important difference between HPV-positive and
HPV-negative tumors in a study of clinical
correlates from Sweden [39]. Patients with
HPV-related cancers, identified by DNA PCR,
were younger, with a mean age of 59 years
(range 42–78) compared to patients with
HPV-negative tumors, who had a mean age of
66 years (range 45–89).
Overall population trends in the US SEER
data have shown the incidence of
oropharyngeal squamous cell cancer is higher
in men compared to women and more common
in black people compared to other races [3].
However, when HPV-related cancers are
examined these trends are different.
HPV-related oropharyngeal cancers have been
seen specifically in white men and an increasing
incidence trend for men compared to women in
other races [3]. There is also an association
between educated middle class patients and
HPV-positive cancers [38].
Tobacco use is a well-known risk factor for
head and neck cancer and has a synergistic
effect with alcohol [40]. They have been
identified as major risk factors for head and
neck and oropharynx carcinoma in a large
multicenter consortium study including
25,500 patients [41]. However, studies
investigating patients with HPV-positive
tumors report patients are more likely to be
non-smokers [42], and overall tobacco use is
lower compared to patients with HPV-negative
tumors. Cohorts of patients with HPV-positive
tumors consist of about 30% nonsmokers
compared with less than 5% in the
HPV-negative groups [43]. This relationship
has been reported in many studies [44].
However, smoking in patients with HPV 16
infection has recently been examined in the
NHANES survey in the US [45]. In the 6887
participants, bivariable analysis reported
tobacco use was associated with HPV 16
infection. Therefore, there is more to
understand about the interaction of tobacco
and HPV infection. The effect of tobacco use on
prognosis and outcomes is discussed below.
Infection of the uterine cervical and
ano-genital region with high-risk HPV is
transmitted through sexual contact [8].
Therefore, the mode of infection of high-risk
HPV subtypes in the oropharynx has been
investigated with regard to sexual behaviors.
The transmission of oral HPV is not fully
understood [20], but there is strong evidence
for sexual transmission. In this hospital-based
case–control study of 240 patients with head
and neck cancer and 322 controls, self-reported
sexual behaviors were associated with
HPV-related cancers. The increasing numbers
of lifetime vaginal or oral sex partners,
participation in casual sex, infrequent use of
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barrier protection during vaginal or oral sex,
and having had a sexually transmitted disease
in the past was associated with HPV-positive
tumors. In contrast, no sexual behavior was
associated with patients who had HPV-negative
cancers of the head and neck.
In a case–control trial of 100 patients with
oropharyngeal cancer and 200 non-cancer
controls, multivariate logistical regression was
used to identify risk factors. It found that more
than 26 sexual partners and more than six oral
sexual partners were independent risk factors
for HPV-related oropharyngeal cancer [23].
Further support for a sexual exposure etiology
is found in the increasing incidences of herpes
simplex 1 and 2 genital infections and genital
wart infections in recent birth cohorts. These
are observed as surrogate markers for oral sex,
risky sexual behavior, and HPV exposure [46].
Clinical presentations are also different in
HPV-related oropharyngeal cancers. They
present with smaller primary tumor lesions, but
larger and cystic cervical nodal disease [47].
Therefore, patients often present with nodal
disease, without typical head and neck cancer
risk factors. The primary tumor is often a low T
stage [48] and can be small or not detectable by
clinical examination or radiographic
investigation. The cystic nodal masses can
cause errors in sampling with malignant cells in
solid components of themetastasis beingmissed.
There are also differences in the
histopathology between HPV-positive tumors
and HPV-negative tumors. HPV-positive tumors
are more likely to be non-keratinizing and
undifferentiated. In a study of 253 tumors a
basaloid or poorly differentiated SCC subtype
was associated with viral genome in the tumors
cells [9]. However, the more aggressive
histological features of HPV-related carcinomas
are not related to prognosis or outcomes
following treatment.
Comparison of Outcomes
Survival and therapeutic response was
prospectively studied as part of the Eastern
Cooperative Oncology Group (ECOG) 2399
protocol in which patients with stages III and
IV head and neck cancers were treated with
induction chemotherapy [49]. Following
assessment of response, responders received
chemo-radiation and non-responders received
either surgical resection or chemo-radiation.
Patients with HPV-positive disease had a
higher response rate to induction
chemotherapy and chemo-radiotherapy. They
also had a better overall survival at two years of
95% (95% CI 87–100%) compared with 62%
(95% CI 49–74%) in HPV-negative tumors [49].
There has been a large number of
retrospective studies demonstrating patients
with HPV-positive tumors of the oropharynx
have a better prognosis than patients with
HPV-negative tumors [50]. However, most of
these are small or the study design does not
allow control for confounding factors. As
previously discussed, patients with
HPV-positive tumors tend to be younger,
healthier, non-smokers, and from educated
backgrounds.
The landmark study, performed as part of the
Radiation Therapy Oncology Group (RTOG)
0129 trial planned to assess potential
confounders by including a larger number of
participants so additional factors could be
controlled for [51]. HPV status was identified
as the major independent determinant of
overall survival after controlling for age, race,
tumor and nodal stage, tobacco exposure, and
treatment assignment [51]. At 3 years, there was
a 58% reduction in the risk of death (hazard
ratio 0.42, 95% CI 0.27–0.66) between patients
with HPV-positive tumors and HPV-negative
tumors. This has been reproduced in a number
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of other studies [29, 33, 49, 52]. Figure 2 shows
the Kaplan–Meier curve for overall survival
stratified by HPV status from this study [49].
The use of tobacco was also identified as an
independent factor in the prognosis of patients
with HPV-positive and HPV-negative tumors.
Smoking has also been correlated with a worse
outcome in other studies [49]. However, each
additional pack-year was seen to decrease
survival and following the incorporation of
the tumor, node, metastasis (TNM) stage with
HPV status, and smoking history stratification
was possible. Low-, intermediate, and high-risk
groups were identified [51]. Low-risk patients
include HPV-positive patients with either less
than 10 smoking pack-years or more than 10
smoking pack-years, but N0–N2a nodal disease.
The intermediate group consists of patients
with HPV-positive patients with more than 10
smoking pack-years and N2b–N3 nodal disease
and patients with HPV-negative tumors with
less than 10 smoking pack-years and T2–3
primary tumors. The high-risk group includes
patients with HPV-negative tumors with less
than 10 smoking pack-years, but T4 primary
tumors or had more than 10 smoking
pack-years. Figure 3 shows a summary of the
overall survival for these groups [53].
This trend has been shown in meta-analysis
of studies worldwide. In a meta-analysis
reporting on 5681 patients, the prevalence of
HPV tumors was 22%, and this was associated
with an improved survival with a hazard ratio of
0.42 (95% CI 0.27–0.57) [29].
Factors that Predict Outcome
The implication of HPV status on outcome is
evolving. The traditional TNM classification
system [54] has been reported to be less
effective in predicting cancer-specific mortality
in oropharynx cancers [55]. Prognostic factors
used in HPV-negative tumors such as margin
status, lymphovascular invasion, pN status, and
extra-capsular spread were not predictive in
HPV-positive tumors in a study reported by
Fig. 2 Kaplan–Meier curves for overall stratiﬁed by tumor HPV status for the entire study population [49]. HPV human
papillomavirus. Reproduced with permission from Fakhry et al. [49]
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Iyer et al. [56]. The prognostic factors found in
patients that were treated with initial surgery
and then postoperative radiotherapy are shown
in Tables 1 and 2. It shows distinct differences
between patients with HPV-positive tumors and
HPV-negative tumors. The Kaplan–Meier
survival curves are also shown in Fig. 4.
Molecular (Genomic) Comparison
The reason why HPV-positive and HPV-negative
cancers behave differently is due to the
difference in the mutational landscape of
these cancers. In two studies performing whole
sequencing of exons (all known
protein-encoding genes) in head and neck
cancers published in 2011 [57, 58], dominant
roles were seen for tumor-suppressor pathways
including p53, Rb/INK4/ARF, and Notch in
disease pathogenesis. However, only a small
number of oncogene-activating mutations were
identified. The vast majority of the tumors in
these studies were HPV negative (28/32 and
80/92). These studies found fewer genes were
mutated per tumor in the HPV-associated
tumors as compared with those tumors not
related to HPV [57].
TP53 mutations were not identified in any of
the HPV-positive tumors in one study [57], but
were seen in 78% of HPV-negative tumors.
There was also an increased number in
mutations in tobacco-related cancers
compared to non-tobacco-related cancers.
The Cancer Genome Atlas Network (TCGA)
recently published findings on the assessment
of 279 patients with head and neck cancer,
assessing for somatic genomic alterations [59].
This study has shown a difference between
Fig. 3 Risk classiﬁcation for oropharynx cancer according
to HPV status for OS [53]. Low-risk patients include HPV
positive patients with either less than 10 smoking
pack-years or more than 10 smoking pack-years, but
N0–N2a nodal disease. The intermediate group consists
of patients with HPV-positive patients with more than 10
smoking pack-years and N2b–N3 nodal disease and
patients with HPV negative tumors with less than 10
smoking pack-years and T2–3 primary tumors. The
high-risk group includes patients with HPV-negative
tumors with less than 10 smoking pack-years, but T4
primary tumors or had more than 10 smoking pack-years.
HPV human papillomavirus, OS overall survival. Repro-
duced with permission from Chau et al. [53]
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HPV-positive tumors and HPV-negative tumors.
Helical domain mutations of the oncogene
PIK3CA, novel alterations involving loss of
TRAF3 and amplification of the cell cycle
gene E2F1 are seen in HPV-positive tumors.
In comparison, HPV-negative tumors
demonstrated loss-of-function TP53 mutations
and CDKN2A inactivation with copy number
alterations of 3q26/28 and 11q13/22. Figure 5 is
a graphical description of the results of the
TCGA study comparing gene alterations in 279
HPV-positive and HPV-negative tumors. In
general mutations found in head and neck
cancers involve tumor-suppressor genes rather
than oncogenes. This makes targeting a specific
pathway more difficult.
The molecular alterations can be divided
into the following pathways:
1. p53 and pRb pathways (cell cycling/
limitless replication). HPV-negative tumors
have p53 mutations present in 86% of
patients [59] and have an association with
outcome [60], whereas only 3% of
HPV-positive tumors have similar p53
mutations [59].
2. EGFR pathway (the most studied growth
factor signaling pathway in head and neck
cancers). EGFR expression has been
Table 1 Multivariate analysis showing factors predictive of OS, DSS, and RFS in p16-negative patients that received initial
management with surgery at Memorial Sloan-Kettering Cancer Center [56]
Predictive factor Outcome HPV negative
Hazard ratio (95% CI)
P value
Age[60 years OS 1.7 (1.0–3.1) 0.071a
Lymphovascular invasion OS 2.1 (1.2–3.8) 0.010a
DSS 2.1 (0.9–5.0) 0.082
RFS 2.7 (1.3–5.8) 0.010
Close/positive margin OS 2.1 (1.1–3.9) 0.020a
DSS 3.2 (1.3–7.9) 0.015a
RFS 1.6 (0.7–3.4) 0.234
N-positive neck DSS 0.5 (0.1–1.9) 0.300
Extra-capsular extension OS 1.7 (1.0–2.9) 0.053a
DSS 4.7 (1.3–17.1) 0.019a
RFS 1.5 (0.8–3.1) 0.244
HPV-associated subsite (tonsil/BOT) Not predictive
Perineural invasion Not predictive
Local advanced T stage (T3 and T4) Not predictive
Post-operative RTx Not predictive
Reproduced with permission from Iyer et al. [56]
HPV status inferred from immunohistochemistry for p16
CI conﬁdence interval, DSS disease-speciﬁc survival, HPV human papillomavirus, OS overall survival, RFS recurrence-free
survival, RTx radiotherapy
a Statistically signiﬁcant
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reported in more than 90% of tumors and
high EGFR levels are associated with poor
prognosis, but its role in head and neck
cancer seems to be more complex than first
thought [61]. Current data on the
interaction of HPV status and EGFR
expression is inconsistent [62] and EGFR
pathway alterations were rarely seen in
HPV-positive cancers [59].
3. TGFb pathway (growth factor signaling).
This is an inhibitor of growth pathways and
through cellular SMAD proteins
[portmanteau of mothers against
decapentaplegic (MAD) and the
Caenorhabditis elegans protein SMA, from
genesma for small body size] controls a
number of cell cycle-dependent kinase
inhibitors [35]. It has also been linked
with nuclear factor-jB, which provides an
important survival signal to cells [63]. These
have been linked with metastasis and
invasion [64].
4. PI3K–PTEN–AKT pathway (evading
apoptosis). Activating mutations in PI3K as
well as inactivating mutations of PTEN have
been found, both of which lead to AKT
activation. There are a number of
downstream mediators such as MYC,
mTOR, and MDM2 that are part of this
pathway and they have been implicated in
Table 2 Multivariate analysis showing factors predictive of OS, DSS, and RFS in p16-positive patients that received initial
management with surgery at Memorial Sloan-Kettering Cancer Center [56]
Predictive factor Outcome HPV positive
Hazard ratio (95% CI)
P value
Age[60 years Not predictive
Lymphovascular invasion Not predictive
Close/positive margin Not predictive
N-positive neck Not predictive
Extra-capsular extension Not predictive
Non-HPV-associated subsite (soft palate versus tonsil/BOT) DSS 4.8 (1.3–17.2) 0.016
Perineural invasion OS 1.7 (0.8–3.5) 0.185
RFS 3.0 (1.2–7.5) 0.016
Local advanced T stage (T3/T4 versus T1/T2) OS 3.7 (1.8–7.6) 0.001a
DSS 3.9 (1.5–10.0) 0.004
RFS 5.2 (2.1–12.7) 0.001
Not receiving post-operative RTx OS 2.7 (1.2–5.9) 0.015
Reproduced with permission from Iyer et al. [56]
HPV status inferred from immunohistochemistry for p16
BOT base of tongue, CI conﬁdence interval, DSS disease-speciﬁc survival, HPV human papillomavirus, OS overall survival,
RFS recurrence-free survival, RTx radiotherapy
a Statistically signiﬁcant
Fig. 4 Kaplan–Meier plots showing impact of prognostic
factors on DSS in p16-positive and p16-negative patients.
a pT classiﬁcation, b pN classiﬁcation, c margin status,
d ECS. 5-year DSS and P values based on log rank test
[56]. DSS disease-speciﬁc survival, ECS extra-capsular
spread. Reproduced with permission from Iyer et al. [56]
c
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head and neck cancers [35]. These appear to
feature in over 50% of HPV-positive tumors
and in 30% of HPV-negative tumors [59].
TREATMENT APPROACHES
IN HPV-POSITIVE DISEASE
There are major differences in the risk factors,
demographics, clinical behavior, response to
treatment, and molecular patterns of
HPV-positive tumors compared to
HPV-negative tumors [51, 56]. Treating these
as different disease entities may allow more
tailored treatment, limiting toxicity [65].
At present, HPV-positive and HPV-negative
head and neck cancers are treated the same.
Current treatment is based on the TNM stage of
pathology, patient preferences, co-morbidity,
and the treating physician’s experience [40].
The standard of care for oropharyngeal cancer is
either surgery and post-operative radiotherapy
with or without cisplatin or concurrent
chemo-radiotherapy. The latter is used more
often, especially in cancers of the tonsil and
base of tongue [66, 67].
The approaches to treating patients with
HPV-positive oropharyngeal carcinomas can be
classified into:
1. prevention;
2. modification of current techniques;
3. new targeted therapies.
Prevention using available vaccinations is
discussed below. To identify the current
clinical trials and treatments under
investigation in HPV-positive tumors a search
of the current trials database (https://
clinicaltrials.gov/) was performed (April 30,
2015) using the search terms ‘HPV’ and ‘human
papillomavirus’ in any field. Out of the 683
trials returned in the search, 46 trials were
Fig. 5 A graphical description of the results of The Cancer
Genome Atlas (TCGA) Network study comparing somatic
alterations and altered protein expression that represent
plausible therapeutic targets in HPV-positive and negative
tumors [59]. Important genes are shown with their
associated alteration (key below graph depicts gene
aberration). HPV-positive tumors showed loss of TRAF3,
activating mutations of PIK3CA, and ampliﬁcation of
E2F1. HPV-negative tumors contained amplicons on 11q
with CCND1, FADD, BIRC2, and YAP1, or concurrent
mutations of CASP8 with HRAS, targets for cell cycle
death, and NF-kB. Reproduced with permission from [59]
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identified as related to head and neck cancers.
These clinical trials are summarized into
surgical trials, trials using modification of stan-
dard radiotherapy/chemotherapy techniques,
and new agents and immune therapies.
Prevention
Prevention of a virally related malignancy can
be divided into primary and secondary
prevention [68]. Primary prevention methods
focus on preventing persistent infection with
HPV. Secondary prevention describes methods
of early identification of pre-cancerous lesions
or early stage cancers. The papilloma virus’
self-assembly of the L1 major capsid protein has
allowed for a prophylactic HPV vaccine [69].
The vaccines generate neutralizing antibodies to
the highly visible immunogenic target. There
are two available vaccines, a bivalent HPV 16/18
vaccine (Cervarix, GlaxoSmithKline
Biologicals) and a quadrivalent HPV 6/11/16/
18 vaccine (Gardasil, Merck Sharp and
Dohme). There have been a number of trials
supporting the efficacy of these for women in
uterine cervical, vaginal and vulvar related
diseases [70]. The evidence for efficacy of
vaccination in prevention of oropharyngeal
disease is limited. A proof of concept study in
Costa Rica made use of a randomized controlled
trial (RCT) looking at effectiveness of
vaccination in cervical HPV and tested at the
end of the protocol for oral HPV infection in
5834 women [71]. A significant reduction in
infection was found in the treatment arm
compared to control. Further progress has
been hampered by the limited uptake of
vaccination and the different disease profile of
HPV infection between the two sites. Cervical
HPV infection is associated with age of sexual
debut whilst the risk of oral HPV infection
appears to last longer, requiring a prolonged
immune response from vaccination. Further
developments in this area included the
development and production of new
vaccinations targeting more HPV subtypes
[72]. This new vaccine targets 6, 11, 16, and
18 and five additional oncogenic types 31, 33,
45, 52, and 58. Subtypes 31 and 45 [27] have
been thought to have a small, but significant
role in oropharyngeal cancers of non-HPV 16
type [13, 14].
Techniques for secondary prevention or
screening have been investigated. The use of
an oropharyngeal ‘pap smear’ equivalent was
unfortunately not seen to be useful because
cytological changes associated with dysplasia
were not associated with HPV infection in
patients without obvious lesions [73]. The use
of HPV 16 E6 antibody serology as a blood test
biomarker is under investigation. Although
evidence of HPV 16 infection increases the
likelihood of oropharyngeal cancer [74], a
positive result has been seen in patients over
10 years before cancer development,
questioning the usefulness of it in identifying
treatable patients [75].
De-Intensification of Current Treatments
Surgical Trials for HPV-Positive Cancers
of the Oropharynx
The use of surgery in HPV-positive
oropharyngeal cancer has become focused on
the application of minimally invasive
techniques, including trans-oral laser surgery
(TLS) and trans-oral robotic surgery (TORS).
Although trans-oral surgery is not a new
treatment, new surgical advances and the
changing epidemiology of oropharyngeal
cancer have suggested these as an alternative
approach to the ‘organ preservation
non-surgical’ treatments [76]. Radical radiation
and chemotherapy treatments are achieving
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good clinical responses in patients with
HPV-positive tumors [51], but the treatments
are often associated with unpleasant toxicities
and long-term effects [77, 78]. In the
HPV-positive cohort there is a greater chance
of long-term survival following treatment, in
younger and healthier individuals. Offering
minimally invasive surgery to reduce the
long-term side effects associated with
chemo-radiation is fuelling the desire to
expand these techniques [79].
The role of surgery in these patients is to
reduce adjuvant treatment and potentially to
avoid it [80]. The use of TLS was first
popularized in Europe by Steiner [81], and
whilst there has been increasing experience
with this technique, its use for oropharyngeal
tumors has been small. It has also been limited
to a few high-volume centers in the US [79] and
European units mainly in France and Germany
[80]. The use of the da Vinci (Intuitive Surgical,
Inc.) robot to perform robotic trans-oral surgery
has gained increasing popularity and is being
used increasingly throughout the world. There
are no comparative prospective studies
comparing minimally invasive surgery with
modern chemo-radiotherapy. However, a
number of retrospective cohort studies are
showing promising results [82–84].
Currently the clinical trials database has six
trials investigating the role of minimally
invasive surgery in HPV-positive
oropharyngeal disease. These are summarized
in Table 3.
In the Sinai Robotic Surgery Trial study,
de-escalation based on surgical resection and
neck stage is being assessed in HPV-positive
tumours (ClinicalTrials.gov identifier,
NCT02072148). In a study at the University of
Pennsylvania, robotic surgery is also being used
to de-escalate adjuvant treatment by reducing
treatment to the primary tumor bed in fully
resected tumors (ClinicalTrials.gov identifier,
NCT02225496). In an ECOG 3311 study,
patients are randomized to either normal-dose
postoperative radiation or low-dose treatment
(ClinicalTrials.gov identifier, NCT01898494)
following minimally invasive surgery. This is a
large multicentre study in which patients are
stratified following surgery. Low-risk patients
receive observation post-operatively and
high-risk patients receive chemo-radiotherapy.
Intermediate risk patients are randomized to
low-dose or normal-dose radiotherapy. Figure 6
shows the protocol for the study.
The PATHOS trial (Post-operative adjuvant
treatment for HPV-positive tumours) is a
randomized multicentre trial based in the UK
comparing post-operative treatment following
surgery for HPV-positive disease, which is due to
start soon. Depending on resection and staging
information, patients will be classified as low,
intermediate or high risk. Low-risk patients will
not receive adjuvant treatment. Intermediate
and high-risk patients will be randomized to an
adjuvant treatment. The intermediate risk
group will be randomised to high-dose or
low-dose radiotherapy, and the high-risk group
will be randomized to standard radiotherapy
with or without chemotherapy
(ClinicalTrials.gov identifier, NCT02215265).
In the APEDT trial (post operative adjuvant
therapy de-intensification trial for human
papillomavirus-related, p16? oropharynx
cancer) patients with fully excised
HPV-positive primary tumors will receive
either radiotherapy or radiotherapy and
cisplatin (ClinicalTrials.gov identifier,
NCT01687413). In another study, the use of
post-operative docetaxel with hyper-fractioned
intensity modulated radiotherapy (IMRT) is
being investigated following minimally
invasive surgery with curative intent
(ClinicalTrials.gov identifier, NCT01932697).
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Trials Using Modification of Standard
Radiotherapy or Chemotherapy Techniques
in HPV-Positive Oropharyngeal Tumors
A summary of the trials discussed below can be
found in Table 4.
Cisplatin Alternatives Given with
Radiation EGFR therapies are being used and
investigated as an option for reducing toxicity
in HPV-positive tumors. The most widely used
is cetuximab, a monoclonal antibody that
targets the EGFR extracellular ligand-binding
domain. Following a phase III trial [85],
cetuximab has been approved for use in
Europe and the US in locally advanced head
and neck cancer. Cetuximab has shown
improved overall survival in a patient group
given cetuximab and radiation over radiation
alone, but the study did not test for HPV status
in the tumor specimens.
To answer whether cetuximab is beneficial in
HPV-positive patients, the RTOG is running a
randomized trial of cisplatin versus cetuximab
with radiation (ClinicalTrials.gov identifier,
NCT01302834). A UK based trial called
De-ESCALaTE (Determination of cetuximab
versus cisplatin early and late toxicity events)
is addressing a similar question comparing
either cisplatin or cetuximab with radiation
and focusing on toxicity outcomes
(ClinicalTrials.gov identifier, NCT01874171).
An Australian group TROG (Trans-Tasman
Radiation Oncology Group) are also recruiting
into a trial comparing cetuximab to cisplatin
with radiotherapy (ClinicalTrials.gov identifier,
NCT01855451). A further study investigating a
Fig. 6 The protocol for the Eastern Cooperative Oncology
Group (ECOG) 3311 study (NCT01898494). Patients are
stratiﬁed with low-risk patients receiving observation
post operatively and high-risk patients receive
chemo-radiotherapy. Intermediate risk patients are
randomized to low-dose or normal-dose radiotherapy.
Reproduced with permission from: http://ecog-acrin.org/
clinical-trials/e3311-educational-materials
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cohort treated with cetuximab with pre- and
post-treatment biopsies is also being carried out
and will be compared to a historical series of
cisplatin-treated patients (ClinicalTrials.gov
identifier, NCT01663259).
Cetuximab has been shown to be effective in
head and neck cancer, but recent studies
investigating its use have not shown HPV a
useful predictor of response in EGFR therapies
[52, 86–88]. Additionally, the HPV status of
tumors did not affect the response to cetuximab
in vitro or in vivo in this study [62]. The
findings of the genomic sequencing studies
have also shown that the EGFR pathway
alterations are rare in HPV-positive tumors
[59] and makes the results of the above studies
more important before cetuximab is used
widely in HPV-positive disease.
Reducing Radiation Dose and Modulation of
Radiation Dose Following Induction
Chemotherapy for HPV-Positive
Tumors There are also other trials investigating
different de-intensification treatments based on
the response to induction chemotherapy. In an
ECOG trial, induction chemotherapy with
paclitaxel, cisplatin, and cetuximab will be
followed by cetuximab in combination with
either low-dose or standard-dose IMRT
depending on the response to the induction
chemotherapy (ClinicalTrials.gov identifier,
NCT01084083). The Quarterback Trial
(ClinicalTrials.gov identifier, NCT01706939) is
also comparing a reduced radiation dose with
weekly carboplatin to the standard radiation dose
and weekly carboplatin in patients that have
responded to induction chemotherapy.
Another trial that will de-intensify treatment
based on response to induction chemotherapy
is the OPTIMA trial. Nab-paclitaxel and
carboplatin will be followed by response-based
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or just radiation alone in stages III or IV
HPV-related oropharyngeal cancer
(ClinicalTrials.gov identifier, NCT02258659).
Paclitaxel and carboplatin as induction
therapy before radiation therapy with
concomitant paclitaxel for HPV-positive
patients is undergoing evaluation in another
trial that is currently recruiting
(ClinicalTrials.gov identifier, NCT02048020).
Reduced Radiation Dose in HPV-Positive
Patients In a single intervention group study
(ClinicalTrials.gov identifier, NCT01530997), a
reduced dose of 54–60 Gy of IMRT with
concurrent weekly intravenous cisplatin in
HPV-positive patients will be followed by
surgical resection of any clinically apparent
residual primary tumor or neck disease. A
biopsy of primary site and a limited neck
dissection will be performed in complete
responders.
A randomized trial using patients with
HPV-positive oropharynx tumors is recruiting
using a reduced-dose IMRT treatment with
patients randomized to just radiotherapy alone
or to receive concomitant cisplatin
(ClinicalTrials.gov identifier, NCT02254278).
In this study, treatment de-intensification for
HPV-positive SCC of the oropharynx is being
investigated alongside cisplatin chemotherapy
with a reduced radiation in the experimental
arm from 70 to 63 Gy and from 58.1 to 50.75 Gy
in primary treatment volume and clinical target
volumes respectively (ClinicalTrials.gov
identifier, NCT01088802).
Another trial considered a reduced radiation
dose to the nodal basins but it is currently
suspended (ClinicalTrials.gov identifier,
NCT01891695). A different group had planned
to treat patients with low-risk HPV-related
oropharyngeal SCC and a N0 neck with a
de-intensification of radiation and
chemotherapy (ClinicalTrials.gov identifier,
NCT02281955), but this study has also
suspended recruitment.
A meta-analysis of RCTs that performed post
hoc stratification for HPV analyzed five trials.
They suggested HPV-positive groups were a
heterogeneous population with non-smokers
demonstrating improved survival compared to
smokers. They concluded that
de-intensification in HPV-positive smokers had
to be carefully assessed for safety [86].
New Agents and Immune Therapy
Chemotherapy
Ribavirin is a drug that is used in the treatment
of hepatitis C. It targets the 4E protein and has a
role in ribosome function. HPV-positive tumors
have shown abnormally high levels of this
protein and its utility in HPV-related cancers is
under investigation in the setting of recurrent
or metastatic cancers (ClinicalTrials.gov
identifier, NCT02308241). It is also being
evaluated as part of a phase I trial in
association with induction chemotherapy
including afatinib (a tyrosine kinase inhibitor)
and weekly carboplatin/paclitaxel for stage IV
HPV-associated oropharynx SCC
(ClinicalTrials.gov identifier, NCT01721525).
A PI3K (phosphatidylinositol-3 kinase)
and PLK (Polo-like kinase) signalling pathway
inhibitor called rigosertib is being investigated
in a phase II trial in patients with relapsed or
recurrent disease (ClinicalTrials.gov identifier,
NCT01807546). A phase I trial in which it is
being used as initial treatment with
platinum-based chemo-radiotherapy is also
recruiting (ClinicalTrials.gov identifier,
NCT02107235). A University of Pittsburg study
is planning to use a PI3K inhibitor, BYL719,
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with induction paclitaxel and cisplatin for
HPV-associated oropharyngeal SSC. This will
be followed by surgery to the primary site and
neck with post-operative risk adapted IMRT
(ClinicalTrials.gov identifier, NCT02298595).
In a Phase Ib study of BKM120 (a PI3K
inhibitor), it will be administered with
cisplatin and radiotherapy in high-risk, locally
advanced SCC of the head and neck
(ClinicalTrials.gov identifier, NCT02113878).
In a phase II trial at MD Anderson, a PD-1
(programmed cell death protein) blocker,
nivolumab, and a new HPV-16 vaccination
(ISA101) will be given to HPV-16-positive
incurable solid tumors (ClinicalTrials.gov
identifier, NCT02426892). A planned phase I
and II study of ADXS11-001 (live-attenuated
Listeria monocytogenes cancer vaccine) and
MEDI4736 (anti-PD-L1 antibody) will give
these medications either alone or in
combination to patients with cervical or
HPV-positive head and neck cancer
(ClinicalTrials.gov identifier, NCT02291055).
In a Yale pilot trial ‘Window Trial 5-aza in
HNSCC’, an inhibitor of DNA methylation will
be evaluated in HPV-positive and HPV-negative
oropharyngeal cancers (ClinicalTrials.gov
identifier, NCT02178072).
The activity of a heat shock protein
inhibitor, Hsp90 Inhibitor AT13387, in
treating patients undergoing radiation therapy
and cisplatin in HPV-positive and HPV-negative
tumours is also planned (ClinicalTrials.gov
identifier, NCT02381535).
Immune Therapy and Vaccines
Immune therapy and vaccines offer a different
modality for the treatment of oropharyngeal
SCC that has not been available before. This is
because foreign viral antigens that are present
in cancers cells could be amenable to targeted
therapy. This is supported by the local presence
of HPV16-specific T cell immunity found in
HPV-16-induced SCC [89].
Genetically Modified T Cell Response T cells
can be used as an autologous transfusion in a
process termed adoptive immunotherapy. In
the past, melanoma and viral-associated
malignancies have been responsive to this type
of therapy [90] and it is being investigated for
use in head and neck cancers.
In patients with recurrent HPV-positive
tumors, a team is planning to investigate the
role of HPV-specific T cells. These are T cells that
have been modified to kill HPV-infected cells
through the recognition of the E6 and E7 viral
proteins. They have also been modified to
prevent T cell inactivation that can be
associated with these tumors
(ClinicalTrials.gov identifier, NCT02379520).
The National Cancer Institute (NCI) Surgery
Branch has also developed an experimental
therapy using T-cell receptor immunotherapy
targeting HPV-16 E6 cell surface receptors. T
cells of the patients are genetically modified
using a therapy called gene transfer. These cells
are modified with a virus (retrovirus) to attack
only the tumor cells and then transfused back
into the patient (ClinicalTrials.gov identifier,
NCT02280811). In this phase II trial,
tumor-infiltrating lymphocytes are harvested
from the patient’s tumor and then expanded
before being infused back into the patient
(ClinicalTrials.gov identifier, NCT01585428).
Cancer Vaccines Antitumor vaccines aim to
stimulate a host’s immune system in the
treatment of cancer. Viral-induced cancers are
a particular focus as they are associated with
immunogenic antigens.
Microorganism vaccines In a phase I trial of a
recombinant Listeria monocytogenes-based
vaccine that has been modified to express
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HPV-16 targets (REALISTIC trial), the safety of
the vaccine (ADXS11-001) in patients treated
with oropharyngeal cancer is being assessed
(ClinicalTrials.gov identifier, NCT01598792)
and is hoped to boost a patient’s immune
response to the cancer.
This listeria-based HPV vaccine is also
forming part of a trial based at the Mount
Sinai hospital in the US. They plan to
investigate circulating and tumour-infiltrating
antigen-specific T cells in HPV-16-positive
oropharyngeal cancer patients undergoing
TORS resection (ClinicalTrials.gov identifier,
NCT02002182).
DNA vaccines DNA vaccines are also being
evaluated in the treatment of head and neck
cancers. The delivery method of DNA vaccines
is important and a number of studies are
evaluating electroporation delivery of vaccine
[91]. The efficacy of DNA vaccines in a murine
model has been shown [92] and there is hope
for its use in humans.
This trial had planned to assess the safety of a
DNA vaccine pNGVL4a-CRT/E7 (detox)
administered with an electroporation device
and a low dose of cyclophosamide
(ClinicalTrials.gov identifier, NCT01493154),
but has been terminated due to lack of funding.
A further DNA vaccine, in a phase I
open-label study, plans to evaluate the safety,
tolerability, and immunogenicity of INO-3106
alone or in combination with INO-9012 (an
interleukin 12 vaccine). The DNA vaccines are
delivered by electroporation to subjects with
HPV-16-associated head and neck cancer
(ClinicalTrials.gov identifier, NCT02241369).
A further trial involving the interleukin 12
vaccine (INO9012) and VGX-3100 (two separate
DNA plasmids respectively encoding E6 and E7
proteins of HPV-16 and HPV-18) delivered by
electroporation in subjects with HPV-16 and/or
18-positive head and neck cancer is also in a
phase I trial (ClinicalTrials.gov identifier,
NCT02163057).
Peptide vaccines Peptide immunomodulatory
vaccines against HPV-16 and MAGE-A3
(Melanoma antigen E) have also been
investigated. They have been assessed in
recurrent/metastatic head and neck SCC and
the results of this trial (ClinicalTrials.gov
identifier, NCT00704041) from the University
of Maryland have been published and show
they are well tolerated and stimulate a
potentially meaningful T cell and antibody
response [93]. Another immunomodulatory
peptide, P16_37-63-peptide, is undergoing
assessment in a phase I trial (ClinicalTrials.gov
identifier, NCT01462838) in Germany. A trial
examining a number of patients with advanced
or recurrent HPV-driven cancers were assigned
to receive either HPV E6 or E7 peptide. The
study has completed, but there are no results
currently available (ClinicalTrials.gov identifier,
NCT00019110).
CONCLUSIONS
Oropharyngeal cancer has undergone an
epidemic change in the last 20 years. HPV has
become the leading etiological cause of
oropharyngeal cancer in the developed world
[4]. The differences between tumors caused by
HPV and those related to tobacco smoking and
alcohol are well documented. HPV tumors
generally affect patients that are younger and
more likely to be from a Caucasian and
educated background. These patients tend to
be healthier with less exposure to tobacco and
alcohol, but have risk factors related to sexual
behavior [44].
Patients with HPV-positive tumors present
with small primary lesions that are almost
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exclusively in the tonsil and tongue base, but
can have larger cystic nodal disease. They have a
significantly improved prognosis and better
response to all modalities of treatment [51].
They significantly fewer mutations with
retained p53 wild type while HPV-negative
tumors have an incidence of loss of function
p53 mutations in 80% of tumors [60].
Increasing technological advances has
allowed for more minimally invasive
techniques to become available to the
patients. HPV-positive patients are younger
and healthier and more likely to be cured of
their disease. They, therefore, have a high
chance of living with side effects and toxicities
of treatment. Therefore, a number of strategies
are being investigated to reduce toxicities
related to treatment. Surgical options promise
to reduce the need for adjuvant chemotherapy
and may allow for reduced radiotherapy.
De-intensified radiotherapy and chemotherapy
regimes based on individual risk stratification
offers the hope to tailor treatment and offer a
personalized treatment minimizing risks of
toxicity and maintaining high cure rates.
New chemotherapy agents are currently
being evaluated aimed at HPV-positive disease.
PI3K (phosphatidylinositol-3 kinase) and PD-1
inhibitors hope to exploit the limited
mutational genome of HPV-positive tumors
and target the viral-induced carcinogenic
pathways.
The immunogenic nature of HPV is also
under investigation with treatments aimed at
modifying host immune systems. Cancer
vaccines in the form of microorganism, DNA,
and peptide vaccination offer promise with
significant T-cell response being induced [93].
However, the vaccination of new generations
of the population against HPV infections offers
the greatest potential for the prevention of
virally induced cancer.
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